
    
      The ABY-035 drug molecule is a selective inhibitor of interleukin 17A (IL-17A) that binds
      with high affinity and with a potency corresponding to clinically tested monoclonal
      antibodies in terms of blocking the biological activity of IL-17A. ABY-035 has the potential
      to be an efficacious treatment for a variety of IL-17A-related diseases, including psoriasis
      and psoriatic arthritis.
    
  